Brief: Alphamab Oncology Says Four Ind Applications Accepted By Nmpa Cde For Two Anti-Tumor Bisepecific Antibodies In Pipeline
20/02/2020 01:33
Feb 20 (Reuters) - Alphamab Oncology 9966.HK :
* ALPHAMAB ONCOLOGY- FOUR IND APPLICATIONS ACCEPTED BY NMPA
CDE
FOR TWO ANTI-TUMOR BISEPECIFIC ANTIBODIES IN PIPELINE
Source text for Eikon: ID:nHKS2KDjc9
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)